Originally published In Press as doi:10.1074/jbc.M001422200 on April 17, 2000
J. Biol. Chem., Vol. 275, Issue 26, 20136-20145, June 30, 2000
Ethanol and Arachidonic Acid Increase
2(I) Collagen
Expression in Rat Hepatic Stellate Cells Overexpressing Cytochrome
P450 2E1
ROLE OF H2O2 AND CYCLOOXYGENASE-2*
Natalia
Nieto
,
Patricia
Greenwel
§,
Scott L.
Friedman§,
Fan
Zhang¶,
Andrew J.
Dannenberg
, and
Arthur I.
Cederbaum
**
From the
Departments of Biochemistry and Molecular
Biology and § Medicine and Liver Diseases, Mount Sinai
School of Medicine, New York, New York 10029 and the ¶ Departments
of Cardiothoracic Surgery and
Medicine, Weill Medical
College of Cornell University and Strang Cancer Prevention Center, New
York, New York 10021
Received for publication, February 18, 2000, and in revised form, April 11, 2000
 |
ABSTRACT |
The ability of ethanol and arachidonic acid (AA),
as inducers of oxidative stress and key factors in alcoholic liver
disease, to up-regulate alpha 2 collagen type I (COL1A2)
gene expression was studied in a hepatic stellate cell line
overexpressing the ethanol-inducible cytochrome P450 2E1 (CYP2E1) (E5
cells). A time- and dose-dependent induction in COL1A2
mRNA by ethanol or AA was observed that was prevented by
diallylsulfide, a CYP2E1 inhibitor. Nuclear run-on experiments showed
transcriptional activation of the COL1A2 gene by ethanol
and AA. Catalase abrogated the increase in COL1A2 mRNA suggesting
an H2O2-dependent mechanism.
Cyclooxygenase-2 (COX-2) levels and production of prostaglandin
E2 upon addition of AA were elevated in the E5 cells.
Incubation with NS-398, a COX-2 inhibitor, blocked the effect of AA,
but not of ethanol, on COL1A2 expression suggesting that
CYP2E1 activates COX-2 expression, and the oxidation of AA by COX-2 is
responsible for the increase in COL1A2. Activity of a reporter
construct driven by
378 base pairs of the proximal promoter region of
the COL1A2 gene increased in E5 but not control cells and
was further increased by ethanol or AA. These experiments link
CYP2E1-dependent oxidative stress to induction of COX-2 and
the actions of ethanol and AA on activation of collagen gene expression
in hepatic stellate cells.
 |
INTRODUCTION |
Hepatic stellate cells
(HSCs)1 are central to the
fibrotic response to liver injury as these cells undergo activation
with an increase in extracellular matrix deposition during fibrogenesis (1). Induction of collagen type I gene expression is a key component of
increased fibrogenesis by stellate cells (2). Reactive oxygen species
and lipid peroxidation have emerged as important stimuli to collagen
gene induction in HSCs (3).
CYP2E1 is an important source of reactive oxygen species in
alcohol-induced liver injury and fibrosis, generating superoxide (O2·
) and hydrogen peroxide
(H2O2) (4-6). To examine the role of intracellular generation of reactive oxygen species in inducing the
expression of COL1A2, we previously established an HSC line that overexpresses CYP2E1 and found, in the absence of exogenous substrate, a 3.5- to 4-fold increase in COL1A2 mRNA compared with control cells (7). This increase was related to CYP2E1-derived reactive
oxygen species, because it was prevented by antioxidants (7). In this
study, we hypothesized that ethanol could further increase COL1A2
mRNA by a CYP2E1-dependent mechanism, because 1) CYP2E1
metabolizes ethanol to acetaldehyde (8) or reactive radical species
such as the 1-hydroxyethyl radical (9), and 2) ethanol elevates CYP2E1
levels by increasing the stability of the protein (10, 11).
In addition to effects of ethanol metabolism, recent evidence
implicates dietary fat as contributing to the severity of alcoholic liver disease. In animal models, for example, diets containing saturated fatty acids protect against alcohol-induced liver injury, whereas polyunsaturated fatty acids enhance the toxic potential of
ethanol as measured by fatty liver, inflammation, necrosis, and
fibrosis (12). At the molecular level, saturated dietary fat combined
with ethanol diminishes lipid peroxidation, the activity of CYP2E1, and
the synthesis of vasoactive and inflammatory eicosanoids by
cyclooxygenase (COX) (13, 14). In contrast, polyunsaturated fatty acids
such as linoleic acid are a requirement for the development of
alcoholic liver disease; the conversion of linoleic acid to arachidonic
acid (AA) and its subsequent metabolism may play an integral role in
the pathogenesis of alcoholic liver disease (13, 14). AA, as a
component of cell membranes, is a target for autoxidation and it is
susceptible to lipid peroxidation (13, 14), and lipid
peroxidation-derived products such as malondialdehyde and 4-hydroxynonenal can increase collagen expression (15).
Cell culture models have been developed to explore the relationships
between ethanol, AA, and CYP2E1 in mediating liver cell injury by
oxidant stress. By overexpressing CYP2E1 in HepG2 cells, for example,
AA can lead to oxidant stress-dependent toxicity (16). To
date, however, no studies have explored the impact on fibrogenesis of
oxidant stress generated by metabolism of ethanol or AA by CYP2E1. In
this work, the oxidant stress derived from metabolism of ethanol or AA
in CYP2E1-expressing HSC was found to be directly fibrogenic.
Mechanistic studies reveal a critical role for
H2O2 in the up-regulation of COL1A2
expression by ethanol and AA; moreover, COX-2 mediates the
AA-mediated induction of COL1A2 expression.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture and Transfection Experiments--
This study
employed a rat stellate cell line (HSC-T6) (17). The cells contain
intracellular filaments typical of primary HSCs, express desmin, alpha
smooth muscle actin, vimentin, and glial fibrillary acidic protein,
take up and esterify retinol and retinol-binding protein, and are
otherwise similar to primary stellate cells (17). A stable cell line
that overexpresses CYP2E1 (E5), as well as stable cell lines
transfected with either the empty vector pCI-neo (D21) or CYP2E1 in the
antisense orientation (F11), were previously established (7). Cells
were cultured in minimum essential medium supplemented with 10% fetal
bovine serum, 100 units/ml of penicillin, 100 µg/ml of streptomycin, 2 mM glutamine, and 0.5 mg/ml of G-418 in a 5%
CO2-humidified atmosphere. The amount of fetal bovine serum
was reduced to 5% following transfections and/or when cells were
incubated with ethanol or AA. Cell viability assays were performed for
each treatment using the 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay as
described previously (7). Protein concentration was determined by the
method of Lowry et al. (18).
Reporter DNA constructs containing upstream sequences of the
COL1A2 promoter linked to the chloramphenicol acetyl
transferase (CAT) gene were provided by Dr. Francesco
Ramirez (Mount Sinai School of Medicine) (19). In these constructs,
COL1A2 sequences span from
3500 to +58 base pairs
(
3500COL1A2-CAT), from
772 to +58 base pairs
(
772COL1A2-CAT), or from
378 to +58 base
pairs (
378COL1A2-CAT) (19). Parallel
transfections of the corresponding empty vector pEMBL8-CAT
at equivalent concentrations were performed in all experiments.
Plasmid DNA for transfection was prepared by the alkaline lysis method
using the EndoFreeTM Maxiprep kit (Qiagen, Valencia, CA)
followed by double CsCl-ethidium bromide gradient centrifugation
(20).
Cells were trypsinized 16 h prior to transfection and seeded at a
density of 2.5 × 105 cells per 10-cm dish. Fresh
medium was added 2 h before the transfection. Complexes containing
FuGENE 6 (Roche Molecular Biochemicals) plus plasmid DNA were prepared
according to the manufacturer's instructions with a final
concentration of plasmid DNA for each of the chimeric COL1A2
DNA constructs of 0.5 µg/ml. Parallel co-transfections with 0.01 µg/ml of the control pRL-null and TK-luciferase vectors (Promega,
Madison, WI) containing the cDNA encoding the Renilla or
firefly luciferase enzymes were performed in all the experiments to
normalize for the transfection efficiency. The cells were incubated in
the presence of the transfection mix for 6 h, after which the media was replaced. Two h later, 50 mM ethanol or 20 µM AA were added to some of the cells. Cells treated with
ethanol (and controls) were incubated in parafilm-sealed plates. After
overnight incubation, a second dose of ethanol or AA was added. CAT
activity was determined 48 h after the transfection using a
commercial kit (Promega). An extract of cytosolic protein (0.2 or 10 µg) obtained by three cycles of freeze-thawing in 0.25 M
Tris buffer, pH 7.5, was used in each assay, and the CAT reaction was
carried out for either 6 min or 1 h. After extraction with ethyl
acetate, the samples were loaded onto TLC plates, and the acetylated
chloramphenicol was separated from the remaining chloramphenicol by
liquid chromatography in chloroform:methanol (97:3). The intensity of
the signal was detected using a Molecular Dynamics PhosphorImager
(Sunnyvale, CA) and quantified using Image Quant software. Luciferase
activity was assessed using the dual luciferase assay kit (Promega).
Final values were corrected by protein and by the efficiency of
transfection and expressed as a percentage of acetylation of chloramphenicol.
Oxidative Stress--
The intracellular amount of
H2O2 and lipid peroxidation produced in the
presence of ethanol or AA was detected by the 2', 7'-dichlorofluorescein diacetate (DCF-DA) method and by the
peroxidative degradation of cis-parinaric acid,
respectively, according to published protocols (21, 22) as described
previously for these cell lines (7).
Northern Blot Hybridization and Nuclear Run-on Assay--
Total
RNA was isolated using the TRIzol reagent (Life Technologies, Inc.,
Grand Island, NY). 5 µg of RNA were electrophoresed under denaturing
conditions in 0.9% agarose/formaldehyde gels, transferred onto nylon
membranes, and hybridized to random-primed 32P-labeled
complementary DNA (cDNA) probes as described previously (7). The
probes used were a cDNA clone, Hf1131, coding for COL1A2
(23) and an S14 ribosomal protein cDNA clone
purchased from the American Type Culture Collection (Manassas, VA). To
determine the rate of COL1A2 transcription after ethanol or
AA treatment, nuclear run-on assays were carried out as described
previously (7). The labeled nuclear RNAs were purified and hybridized to 8 µg of each cDNA fragment that had been immobilized onto a nylon membrane. This amount of cDNA was calculated to represent a
large excess over the amount of transcribed mRNA. Quantitative comparison of the intensity of the signal scanned in the Phosphorimager was performed using Image Quant software, and values were corrected using the S14 ribosomal protein signal as a control.
Western Blot Analysis--
Western Blot Analysis was performed
with 30 µg of total cell protein according to already published
protocols (24) using rabbit polyclonal anti-COX-2 antiserum (Oxford
Biomedical Research, Oxford, MI) as the primary antibody and IgG
conjugated to horseradish peroxidase as the secondary antibody.
Prostaglandin E2 Production--
The levels of
prostaglandin E2 released to the medium by the D21 and E5
cells incubated in the presence or absence of 10 µM AA
for 30 min were determined using an enzyme immunoassay kit (Cayman
Chemicals, Ann Harbor, MI) as described previously (24). Production of
prostaglandin E2 was normalized to total cell protein concentration.
Statistics--
Results refer to mean ± S.E. and are
average values from three to six values per experiment; experiments
were repeated at least twice. Comparisons among groups were made using
the Student's t test.
 |
RESULTS |
Ethanol and AA Are Not Toxic to Rat HSC--
To evaluate the
effect of ethanol and AA on collagen expression under oxidative stress
conditions, HSC-T6 (17) cells were transfected with the human
CYP2E1 cDNA in the sense and antisense orientation as
well as with the empty vector (pCI-neo), and stable cell lines referred
to as E5, F11, and D21 cells, respectively, were developed (7). The
clone expressing the highest level of CYP2E1 (E5 cells) was used in all
the experiments described below. CYP2E1 expression was validated before
each experiment by assaying for p-nitrophenol oxidation and
by Western blot using human liver microsomes as a positive control. To
evaluate for toxicity, 15 × 103 cells were seeded onto
24-well plates and incubated overnight. In some wells, 25, 50, or 100 mM ethanol or 10, 20, or 30 µM AA was added
to the culture medium for 0, 6, 12, and 24 h, and the viability
after each treatment was assessed by the MTT assay. The average values
of cells grown in regular medium were considered as the 100%
viability; no toxicity greater than 10% was observed in any of the
ethanol or AA treatments at any of the indicated time or dose points
(data not shown).
Oxidative Stress in E5 Cells--
Ethanol induction of CYP2E1 may
contribute to the generation of a state of intracellular oxidant stress
in the liver (25-30). The production of H2O2
in the E5 cells was evaluated in the presence or absence of 50 mM ethanol or 20 µM AA. Endogenous production of reactive oxygen species such as H2O2 was
monitored by the increase in the green fluorescence spectrum of
dichlorofluorescein, a product of the de-esterification of DCF-DA and
oxidation of dichlorodihydrofluorescin. Ethanol treatment of E5 cells
increased H2O2 production by 30% when compared
with the control group (p < 0.05), whereas no
significant changes were observed in the presence of AA (Fig.
1A). Several studies have
emphasized the important role of CYP2E1 in the enhanced microsomal
lipid peroxidation after chronic ethanol consumption (26, 27, 30-32).
Therefore, the levels of lipid peroxidation in the E5 cells incubated
in the presence or absence of ethanol or AA was evaluated by studying
the quenching of fluorescence of cis-parinaric acid. A 15%
increase in the peroxidative degradation of cis-parinaric
acid was detected in the presence of AA when compared with the
non-treated cells (p < 0.05, Fig. 1B).
Ethanol did not promote lipid peroxidation, although it did increase
H2O2 production. The E5 cells, in the absence
of ethanol or AA, were previously shown to display high rates of
reactive oxygen production compared with the D21 and F11 cells (7).
Hence, the modest effects of ethanol or AA occur in cells already
producing high levels of reactive oxygen species.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
A, Effect of ethanol and arachidonic
acid on intracellular H2O2 production in E5
cells. 5 × 105 cells were seeded onto 10-cm dishes.
24 h later the cells were incubated in the presence or absence of
50 mM ethanol or 20 µM AA for 24 h.
DCF-DA was added for 30 min at a final concentration of 20 µM, samples were collected, and relative fluorescence was
analyzed in the spectrofluorimeter using 485-nm excitation and 535-nm
emission filters. B, Effect of ethanol and arachidonic acid
on lipid peroxidation in E5 cells. Cells were incubated in the presence
or absence of 50 mM ethanol or 20 µM AA for
24 h. cis-Parinaric acid was added for 30 min at a
final concentration of 20 µM, samples were collected, and
the relative fluorescence intensity was measured at emission and
excitation wavelengths of 413 and 325 nm, respectively. Results refer
to relative units of fluorescence per mg of protein with the
non-treated E5 cells assigned a value of 1, and they are expressed as
mean ± S.E. n = 3. *, p < 0.05 when compared with values of control ( ).
|
|
Ethanol and AA Induce COL1A2 mRNA in a Time- and
Dose-dependent Manner in E5 Cells--
We previously
demonstrated that overexpression of CYP2E1 in HSC increased COL1A2
mRNA levels even in the absence of any added substrate (7). To
evaluate whether ethanol and AA could further increase COL1A2 mRNA
levels, time course and dose-response experiments were carried out.
Northern blots were performed in the presence or absence of 25, 50, and
100 mM ethanol or 10, 20, and 30 µM AA, and
mRNA levels were quantified as the ratio of COL1A2:s14 (Fig.
2, A and C). COL1A2
mRNA did not change with any of the treatments in the D21 or F11
cells; the COL1A2:s14 ratio for the untreated D21 cells was assigned a
value of 1. As described previously (7), the E5 cells had a 3.5- to
4-fold increase of COL1A2 mRNA levels over values for the D21 or
F11 cells. When E5 cells were treated with 25, 50, and 100 mM ethanol for 24 h there was a further increase in
the COL1A2 mRNA levels (Fig. 2A). After incubation for
24 h with 50 mM ethanol, there was a 2-fold increase
in COL1A2 mRNA. Similarly, AA had no effect on COL1A2 mRNA
levels in the D21 or F11 cells but produced a
concentration-dependent increase in E5 cells (Fig.
2C). Incubation for 24 h with 20 µM AA
produced a 2-fold increase in COL1A2 mRNA expression. To study the
effect of the time of incubation, cells were treated with 50 mM ethanol and 20 µM AA for 0, 6, 12, and
24 h. Time-dependent increases of COL1A2 mRNA
levels by ethanol or AA were only observed in HSC where CYP2E1 was
overexpressed (Fig. 2, B and D). COL1A2 mRNA expression was increased about 8-fold at 24 h with ethanol and AA
treatment in the E5 cells compared with the D21 cells. Because ethanol
or AA induced no measurable changes in COL1A2 mRNA levels at any
time or dose in the D21 or F11 cells, subsequent experiments described
below were carried out only in E5 cells.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Ethanol and AA induce COL1A2 mRNA in a
time- and dose-dependent manner in E5 cells. 5 × 105 HSCs transfected with either the empty vector
(D21, - - -), CYP2E1 (E5, ), or CYP2E1 in the
antisense orientation (F11, . . . . . .) were seeded onto
10-cm dishes for 24 h. The cells were treated with 0, 25, 50, or
100 mM ethanol for 24 h (A); 50 mM ethanol for 0, 6, 12, and 24 h (B); 0, 10, 20, or 30 µM AA for 24 h (C); and 20 µM AA for 0, 6, 12, and 24 h
(D). Total RNA was isolated and Northern blots to
detect COL1A2 and S14 ribosomal protein mRNAs were carried out.
Results are expressed as relative COL1A2 mRNA expression with the
empty vector group (D21) assigned a value of 1 and refer to mean ± S.E. (n = 3 for all the experiments). In all cases,
no significant changes by ethanol or AA were observed in cells
transfected with the empty vector or CYP2E1 in the antisense
orientation. All values were corrected for differences in loading using
the S14 ribosomal protein signal. ***, p < 0.001 when
compared with values of the no ethanol or no AA-treated E5 cells.
|
|
Antioxidants Inhibit the Ethanol- or AA-mediated COL1A2 mRNA
Induction--
As described above, ethanol treatment increased
H2O2 production, whereas AA treatment produced
a modest increase in lipid peroxidation in E5 cells; increases in
reactive oxygen species production by CYP2E1 metabolism of ethanol or
AA were likely to be responsible for the increase of COL1A2 mRNA.
To evaluate whether antioxidants prevented the induction of collagen
mRNA, dose-response curves were performed by preincubating the
cells for 6 h prior to 50 mM ethanol or 20 µM AA treatment in the presence or absence of
antioxidants. Catalase led to a concentration-dependent
inhibition of COL1A2 mRNA levels in the E5 cells (Fig.
3A). Catalase also prevented
the increase in COL1A2 mRNA produced by ethanol or by AA, whereas
catalase inactivated by boiling had no effect (Fig. 3A).
Vitamin E is the principal lipid-soluble antioxidant in biological tissues and is widely used to prevent the onset of cell damage consequent to the induction of lipid peroxidation (32). However, vitamin E did not affect the stimulation of COL1A2 mRNA by
ethanol (Fig. 3B), which is consistent with the lack of
increase in lipid peroxidation by ethanol (Fig. 1B). To our
surprise, vitamin E did not prevent or decrease the stimulation of
COL1A2 mRNA by AA (Fig. 3B). Trolox, a synthetic vitamin
E analogue, also did not prevent the increase in COL1A2 mRNA by AA
(data not shown).

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of antioxidants on COL1A2 mRNA
levels in E5 cells. Experiments were carried out with untreated E5
cells or E5 cells treated with 50 mM ethanol or 20 µM AA for 24 h in the absence or presence of the
indicated antioxidants (Catalase, Vitamin E,
PBN, and Ebselen). Concentrations of the various
additions are listed at the top of the blots. The
antioxidants were added to the cells 6 h prior to the addition of
medium (labeled as -), ethanol, or AA. Total RNA was
isolated after incubation for an additional 24 h, and Northern
blots to detect COL1A2 and S14 mRNA were carried out using 5 µg
of total RNA. All values were corrected for the differences in loading
using the S14 ribosomal protein signal. Results are expressed as
relative COL1A2 mRNA expression, with the untreated E5 cells
(labeled as -) assigned a value of 1.
|
|
N-t-butyl-
-phenyl-nitrone (PBN), a
spin-trapping reagent that reacts with many radicals, including
superoxide, hydroxyl, lipid, and 1-hydroxyethyl radicals (33), produced
a concentration-dependent decrease in COL1A2 mRNA
levels in the E5 cells and completely prevented the increase by AA
(Fig. 3C). Ebselen, a seleno-organic drug with
anti-inflammatory properties that mimics the glutathione peroxidase
reaction (34), as well as the phospholipid hydroperoxide glutathione
peroxidase reaction (35), lowered COL1A2 mRNA levels in the E5
cells (higher concentrations than 25 µM were toxic to the
cells and could not be studied) and completely prevented the increase
by AA (Fig. 3C) (these concentrations of PBN and ebselen were not toxic).
Diallylsulfide (DAS), a CYP2E1 Inhibitor, Prevents the Induction of
COL1A2 mRNA by Ethanol and AA--
To confirm that the effect of
both ethanol and AA on COL1A2 mRNA in the E5 cells is mediated by
CYP2E1, cells were preincubated in the presence or absence of 1 mM DAS (7) 12 h before the addition of ethanol or AA.
Cells were further incubated for 24 h, and COL1A2 mRNA
expression was analyzed by Northern blot analysis. DAS, an effective
inhibitor of CYP2E1 (36), reduced the COL1A2 mRNA levels in the E5
cells and completely abolished the increase in COL1A2 mRNA produced
by ethanol or AA (Fig. 4). These data indicate that CYP2E1 plays a role in the enhanced COL1A2 expression in
the E5 cells and in the further increase produced by either ethanol or
AA.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
Diallylsulfide, a CYP2E1 inhibitor, blocks
the induction of COL1A2 mRNA by ethanol and AA. 5 × 105 E5 cells were seeded onto 10-cm dishes and preincubated
for 12 h with or without 1 mM DAS before the addition
of either 50 mM ethanol or 20 µM AA, followed
by incubation for an additional 24 h. Northern blot analysis was
performed with 5 µg of total RNA hybridized to COL1A2 and S14
ribosomal protein cDNAs. Results are expressed as relative COL1A2
mRNA expression, with the non-DAS-treated E5 cells assigned a value
of 1, and refer to mean ± S.E. (n = 3). ***,
p < 0.001 when compared with the untreated E5 cells;
  , p < 0.001 when compared with the DAS
appropriate group (untreated, ethanol, or AA).
|
|
Ethanol and AA Increase COL1A2 mRNA at the Transcriptional
Level--
To determine the mechanisms responsible for the increase in
COL1A2 mRNA by ethanol or AA, nuclear run-on experiments were performed with nuclei isolated from the E5 cells. The rate of transcription of the collagen gene was compared with that of the S14 ribosomal protein gene as a control. Equal amounts
(106 cpm/ml) of nascent transcripts of nuclei from cells
treated in the presence or absence of ethanol or AA were hybridized to
cDNAs immobilized onto nylon membranes. Cells incubated with
ethanol or AA had a transcriptional rate of the (COL1A2 gene
that was 75 or 100% greater than that of the non-treated cells (Fig.
5A) (p < 0.001). These increases are similar to the increased level of COL1A2
mRNA produced by ethanol or AA (about 2-fold). Previous observations demonstrated that the CYP2E1-dependent
increase in COL1A2 mRNA levels, in the absence of any added
substrate, involved both transcriptional activation of the COL1A2
gene and stabilization of the mRNA (7).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
A, ethanol and AA induce the
transcription of the COL1A2 gene in E5 cells. Nuclear in
vitro run-on assays were performed in triplicate using nuclei
isolated from E5 cells treated with or without 50 mM
ethanol or 20 µM AA for 24 h. A representative assay
of labeled nuclear RNAs hybridized to COL1A2 and S14 cDNA fragments
is shown. B, the effect of actinomycin D on COL1A2 mRNA
synthesis induced by ethanol or arachidonic acid. E5 cells were
incubated with or without 10 µg/ml of actinomycin D for 2 h
prior to adding 50 mM ethanol or 20 µM AA.
24 h later, total RNA was isolated and analyzed for COL1A2
mRNA. A representative Northern blot of 5 µg of RNA in the
absence or presence of actinomycin D is shown. The arbitrary units for
the untreated E5 cells are considered as 1. Results refer to the
mean ± S.E. ***, p < 0.001 when compared with
values of the untreated E5 cells;   , p < 0.001 comparing the effects of ethanol or AA in the presence of actinomycin D
to the effects in the absence of actinomycin D.
|
|
To further validate that the increased COL1A2 mRNA produced by
ethanol or AA was due to increased synthesis of the mRNA, the effect of actinomycin D was evaluated. Previous studies of mRNA stability (7) showed that at 24 h, COL1A2 mRNA decayed by 50% in the D21 cells, whereas no degradation was observed in the E5 cells,
consistent with increased mRNA stability. When E5 cells were
preincubated with 10 µg/ml of actinomycin D for 2 h prior to
ethanol or AA treatment, no increases in mRNA levels were observed when compared with the non-treated E5 cells (Fig. 5B); thus,
actinomycin D blocked the increase in COL1A2 mRNA produced by
ethanol or AA. To confirm that actinomycin D had indeed blocked
transcription, the same membrane was reprobed for S14 ribosomal
protein, which has a half-life of about 3 h; as expected, this
mRNA could not be detected in cells incubated with actinomycin D
for 24 h (data not shown). The addition of actinomycin D did not
change the mRNA level of the untreated E5 cells, consistent with
the stabilization of COL1A2 mRNA found in these cells. Thus, the
nuclear run-on and actinomycin D results collectively suggest that the
effect of ethanol and AA on COL1A2 mRNA expression in the E5 cells
involves transcriptional activation and new mRNA synthesis.
Increased Levels of COX-2 and Prostaglandin E2
Production in E5 Cells--
Because only a small increase in lipid
peroxidation was observed after AA treatment in the E5 cells (15%
when compared with non-treated E5 cells) and neither vitamin E nor
trolox were effective in preventing the AA-induced increase in COL1A2
mRNA, we considered the hypothesis that other AA metabolic pathways
could be responsible for the increase in the steady-state levels of
COL1A2 mRNA after AA treatment. An increase in COX levels has been
described in non-parenchymal cells in experimental alcoholic liver
disease (37). Studies have shown that oxidant status can be a
determinant of both the rate of transcription of COX-2 and
its enzymatic activity (38). The amount of COX-2 was
markedly increased as assessed by Western blot in E5 cells compared
with T6, D21, and F11 cells (Fig.
6A). To determine whether this
enzyme was functional, synthesis of prostaglandin E2 was
measured. As shown in Fig. 6B, when AA was supplemented, E5
cells produced 22-fold more prostaglandin E2 than did D21
cells. The observed increase in prostaglandin E2 synthesis
by E5 cells was blocked by NS-398, a known specific inhibitor of COX-2
(39).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
A, CYP2E1 induces COX-2 expression.
Cellular lysate (30 µg of protein) was resolved in a 10% SDS
polyacrylamide gel followed by Western blot using rabbit polyclonal
anti-COX2 antibody. Lane 1, HSC-T6 (T6) cells;
lane 2, HSC transfected with the empty vector
(D21); lane 3, HSC transfected with CYP2E1
(E5); lane 4, HSC transfected with CYP2E1 in the
antisense orientation (F11). B, CYP2E1
overexpression enhances the production of prostaglandin E2. 5 × 105 D21 or E5 cells were seeded, and after overnight
incubation, fresh minimum essential medium containing 5% fetal bovine
serum with (+) or without (-) 10 µM
AA was added. Some of the E5 cells were incubated in the presence of
NS-398 2 h prior to AA treatment. After 30 min, the medium was
collected for analysis of prostaglandin E2 by enzyme
immunoassay. Results are expressed as pg/µg of protein and refer to
mean ± S.E. (n = 4). ***, p < 0.001 when compared with D21 cells incubated with AA;   ,
p < 0.001 when compared with the NS398-treated E5
cells.
|
|
NS-398, a Selective COX-2 Inhibitor, Blocks the Increase in COL1A2
mRNA Levels Produced by AA--
To evaluate a role for COX-2 in
regulating COL1A2 mRNA levels, cells were preincubated in the
presence of either 1 or 10 µM NS-398 for 2 h and
then treated with or without ethanol or AA for 24 h. To validate
that NS-398 did not affect the endogenous COL1A2 mRNA, cells
transfected with the empty vector were also incubated in the presence
of the COX-2 inhibitor. NS-398 had no effect on COL1A2 mRNA levels
in the D21 cells and did not prevent the increase in this mRNA in
E5 cells (Fig. 7). NS-398 also did not
prevent the further increase in COL1A2 mRNA produced by ethanol in
the E5 cells. However, the increase in COL1A2 mRNA produced by AA
was completely blocked by NS-398 (Fig. 7).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 7.
The effect of NS-398, a selective COX-2
inhibitor, on COL1A2 mRNA levels. 5 × 105 D21
or E5 cells were seeded onto 10-cm dishes. After overnight incubation,
NS-398 was added to the media at a final concentration of either 1 or
10 µM. 2 h later, the E5 cells were treated with 50 mM ethanol or 20 µM AA. RNA was isolated from
all cells after incubation for another 24 h. A representative
Northern blot is shown in panel A, and a summary histogram
is shown in panel B. The relative COL1A2 mRNA
expression of the untreated D21 cells are assigned a value of 1. Results for the E5 cells experiments refer to the mean ± S.E.
***, p < 0.001 when compared with the E5 cells.
|
|
Identification of the Minimal Sequences of the COL1A2 Promoter
Required for CYP2E1-mediated Activation and Response to Ethanol and
AA--
Transient transfection experiments with chimeric constructs
harboring progressive 5' deletions of the COL1A2 promoter
linked to the CAT reporter gene were performed to identify
the promoter regions of the COL1A2 gene required for
CYP2E1-mediated activation and the further up-regulation by ethanol and
AA. D21 and E5 cells were transfected with the constructs shown in Fig.
8A or with the parental empty
vector pEMBL8-CAT. As shown in Fig. 8B, the basal
percentage of acetylation of chloramphenicol in E5 cells transfected
with either one of the COL1A2 promoter-driven vectors was
significantly higher than activity found in transfected D21 cells.
These data are consistent with our previous findings that CYP2E1-dependent COL1A2 activation is exerted,
at least in part, at the transcriptional level (7). Interestingly, the
activities of the
3500COL1A2-CAT and
378COL1A2-CAT plasmids in E5 cells were very
similar (52 and 56% acetylation of chloramphenicol, respectively). On
the other hand, the activity of the
772COL1A2-CAT vector was significantly lower (5.6% in E5 cells; Fig.
8B). These data are in agreement with previous results
reported by other investigators using fibroblasts or HSC, which have
shown that the
772 to
378 region of the COL1A2 gene
contains negative regulatory elements (19, 40). Addition of either 50 mM ethanol or 20 µM AA further increased the
activity of the
378COL1A2-CAT plasmid in E5
cells (5-fold; Fig. 8C). In contrast to these results,
activities of the
3500COL1A2-CAT and
772COL1A2-CAT vectors remained unchanged. Overall, these results suggest that in E5 cells, the
378 to +58 region of the COL1A2 gene is essential for increased basal
COL1A2 expression, as well as for their responsiveness to
ethanol and AA. For comparative purposes, Fig. 8C also shows
the effect of TGF-
, a well known stimulus to collagen synthesis, on
the expression of the different chimeric constructs in E5 cells.
TGF-
increased COL1A2 mRNA levels in E5 cells (data not shown).
As shown in Fig. 8C, the extent of the response to TGF-
in cells transfected with the
378COL1A2-CAT
vector is very similar to that exerted by ethanol or AA. TGF-
increased approximately 2-fold the activity of the
3500COL1A2-CAT vector.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 8.
Identification of the minimal sequences of
the COL1A2 promoter required for CYP2E1-, ethanol-, or
AA-mediated activation. Transient transfection experiments with
different chimeric constructs of the COL1A2 promoter linked
to the CAT reporter gene, as well as the empty vector
pEMBL8-CAT, were performed and cell extracts were collected
as described under "Experimental Procedures." A schematic
representation of the CAT reporter vectors driven by various
sequences of the COL1A2 promoter used for transfection
experiments is shown in panel A. Panel B compares
results of D21 and E5 cells to evaluate the minimal sequences required
for CYP2E1-mediated activation of the COL1A2 gene. The CAT
reaction was run with 10 µg of protein for 1 h, and the
acetylated chloramphenicol (AcC) was separated from the
remaining chloramphenicol (C) by thin layer chromatography.
Results were corrected by transfection efficiency and are expressed as
a percentage of acetylated chloramphenicol and refer to the mean ± S.E. ***, p < 0.001 when compared with D21 cells.
Panel C shows the effects of ethanol, AA, or TGF- in E5
cells. 2 h after transfection with the different chimeric
constructs of the COL1A2 promoter linked to the CAT reporter
gene, as well as the empty vector pEMBL8-CAT, cells were
treated with 50 mM ethanol, 20 µM AA, or 8 ng/ml of TGF- . After overnight incubation, a second dose of ethanol,
AA, or TGF- was added, and samples were collected 48 h after
transfection. The CAT assay was run with 0.2 µg of protein for 6 min,
in contrast to the conditions shown in panel B, to lower the
high activity of the untreated E5 cells and avoid saturation of the
system. A representative chromatogram is shown in which the last two
lanes (- and +) refer to non-transfected E5 cells
as a negative control and E5 cell extract incubated with purified CAT
as a positive control. All the experiments were performed in
quadruplicate (except for the TGF- -treated cells), and values refer
to mean ± S.E. after correcting for efficiency of transfection.
***, p < 0.001 when compared with the non-treated E5
cells transfected with the appropriate construct.
|
|
 |
DISCUSSION |
HSCs play a key role in the fibrotic response to liver injury
(41). Activation of stellate cells with an accompanying increase in
collagen production and other biochemical and structural changes is
mediated by cytokines, reactive oxygen species, aldehydes such as
acetaldehyde, and lipid peroxidation-derived products (42). Because
oxidative stress can stimulate stellate cell proliferation and collagen
synthesis in vitro, we established a rat HSC line, which
overexpresses the CYP2E1 isoform of cytochrome P450 (E5 cells) (7).
Yamada et al. (43) reported that CYP2E1 is present in rat
HSC at levels 21% of those found in hepatocytes, whereas Oinonen
et al. (44) observed immunoreactive CYP2E1 at levels of
about 4% of that found in hepatocytes. Casini et al. (45) did not observe expression of CYP2E1 in human stellate cells. CYP2E1
was detectable in T6 cells transfected with the empty vector (D series
of cell lines, Fig. 1; see Ref. 7) and the parental T6 cells. However,
levels were relatively low, about 2% that of human liver microsomes.
Therefore, to evaluate the effects of CYP2E1 on collagen production in
HSC cultures at reasonable time points and concentrations of ethanol
and AA, HSCs overexpressing CYP2E1 were established. The E5 cells
stably and constitutively express CYP2E1 at levels of about 10 to 13%
that of human liver microsomes (7). Whereas it is recognized that these
levels of CYP2E1 are higher (about 5- to 7-fold) than those present in the HSC-T6, overexpression of CYP2E1 in HSC lines provides a unique model to study the direct effects of intracellular oxidative stress on
COL1A2 regulation in response to ethanol or AA. Such studies set the stage for more physiologic models utilizing co-cultures of
hepatocytes and HSC by precisely defining relevant pathways and
mediators. The E5 cells produced increased reactive oxygen species and
a 3.5- to 4-fold increase in COL1A2 mRNA because of transcriptional
activation of the COL1A2 gene as well as stabilization of
its mRNA (7). The present work was undertaken to examine the
ability of ethanol and AA as inducers of oxidative stress and key
factors in the development of liver disease to up-regulate COL1A2
gene expression in E5 cells.
Ethanol and AA produced concentration- and time-dependent
increases in COL1A2 mRNA in E5 cells. Both compounds stimulated another 2-fold increase in COL1A2 mRNA over that produced by
CYP2E1. DAS, a CYP2E1 inhibitor (36), decreased COL1A2 mRNA levels
in the E5 cells and totally prevented the increase by ethanol and AA on
COL1A2 mRNA expression thus validating the role of CYP2E1. In
vivo administration of DAS has been shown to partially protect against alcoholic liver disease in the intragastric model of chronic ethanol administration (29).
In view of the previously demonstrated stabilization of COL1A2 mRNA
in the E5 cells (7), it is likely that the increase of COL1A2 mRNA
by ethanol or AA is due to transcriptional activation of the
COL1A2 gene. Indeed actinomycin D prevented the increase by
ethanol or AA of COL1A2 mRNA indicating that this increase is due
to new mRNA synthesis. The nuclear run-on experiments documented a
1.7- and 2-fold increase in synthesis of COL1A2 mRNA by ethanol and
AA, respectively. This increase parallels that of COL1A2 mRNA. Consistent with these results, in transient transfection assays with E5
cells, ethanol and AA increased the activity of reporter constructs
driven by different sequences of the COL1A2 promoter. Thus,
enhanced COL1A2 mRNA expression by ethanol or AA in the E5 cells
results from transcriptional activation of the COL1A2 gene.
Transient transfection of E5 cells with chimeric constructs driven by
different sequences of the COL1A2 promoter clearly indicate that the
378 to +58 region is essential for CYP2E1-mediated high basal COL1A2 expression and for ethanol and AA
responsiveness. Interestingly, this region of the promoter contains
TGF
1- and acetaldehyde-responsive elements that are also active in
fibroblasts, as well as in HSC (46-49). This element binds several
transcription factors including Sp1, AP1, and/or NF-1 (40, 48-51)
whose transcriptional activity is regulated by changes in the redox
status. Thus, it is conceivable that CYP2E1-induced changes in the
redox potential in E5 cells enhances the transcriptional activity of
these factors, which in turn transactivate COL1A2 gene
expression. Recent studies have implicated H2O2
in stimulating collagen gene expression by acetaldehyde (52) and
TGF-
(53). We now demonstrate that H2O2 also
plays a critical role in the stimulation of COL1A2
expression by CYP2E1. Hence, acetaldehyde, TGF-
, and CYP2E1,
factors known to be produced or increased by chronic ethanol treatment,
may induce collagen gene expression via common
oxidant-dependent mechanisms and at common sites in the
COL1A2 promoter.
Several mechanisms may be involved in ethanol- and AA-mediated
COL1A2 up-regulation. With respect to ethanol, the increase in COL1A2 mRNA may result from the metabolic effects of ethanol. Indeed, the hepatic oxidation of ethanol results in the production of
acetaldehyde (8, 54). Acetaldehyde increases collagen production via an
H2O2-dependent mechanism (52, 55).
Redox changes can also have an impact on collagen metabolism (54). Alternatively, the increase by ethanol in the E5 cells may be due to
enhanced production of reactive oxygen species. The addition of ethanol
to the E5 cells elevated H2O2 levels by 30%.
The ability of catalase to totally prevent the ethanol-induced increase
in COL1A2 mRNA indicates that H2O2 plays a
central role in this increase by ethanol. It is uncertain whether
H2O2 itself or products derived from it such as
the hydroxyl radical, perferryl species, or the 1-hydroxyethyl radical
are ultimately responsible for the increase in COL1A2 mRNA. Because
ethanol can be oxidized to acetaldehyde by the peroxidative activity of
catalase (56), the decrease in COL1A2 mRNA by catalase suggests
that ethanol-derived acetaldehyde is not responsible for the increase
observed in this model. The inability of vitamin E to prevent the
ethanol-induced increase suggests that lipid peroxidation also does not
mediate this effect, consistent with the lack of an effect on lipid
peroxidation by ethanol in the E5 cells. Catalase also decreased basal
COL1A2 mRNA levels in the untreated E5 cells suggesting that
CYP2E1-derived reactive oxygen species such as
H2O2 play a key role in the enhanced expression
of COL1A2 by CYP2E1.
Results with AA proved to be more complex and somewhat surprising. An
initial hypothesis was that lipid peroxidation, produced as a
consequence of the interaction of CYP2E1-derived reactive oxygen
species with AA, would play a key role in the transcriptional activation of COL1A2 by AA. However, only a small increase
in lipid peroxidation was observed upon incubating the E5 cells with AA. More importantly, vitamin E and trolox did not prevent the increase
in COL1A2 mRNA by AA; these agents were added at concentrations that strongly prevent lipid peroxidation and were previously shown to
prevent AA toxicity to HepG2 cells expressing CYP2E1 (16). The increase
by AA was inhibited by catalase, ebselen, and PBN, indicating that
reactive oxygen species played a role in this increase. The inhibition
by catalase (and ebselen) further suggested that
H2O2 might mediate the stimulatory effect of AA
on COL1A2 mRNA, as discussed above for ethanol. However, AA did not
elevate H2O2 levels in the E5 cells. These
results raised the possibility that other metabolic pathways involving
AA might be activating the COL1A2 gene.
Cyclooxygenases (COX-1 and COX-2) catalyze the conversion of AA into
prostaglandins and thromboxanes. COX-1 is constitutively expressed in a
wide variety of tissues, including the liver, whereas COX-2 is a highly
inducible gene that is expressed in response to many proinflammatory
agents and cytokines (57). Reactive oxygen species play an important
role in inflammation as mediators of injury and potentially in signal
transduction. Several studies have linked reactive oxygen species to
the signaling pathways that induce COX-2 expression (58). In cells
incubated in the presence of H2O2, the
COX-2 gene was transiently induced, whereas O2·
was a more potent inducer (38). In view of the
activation of COX-2 transcription by oxidative stress, we
evaluated the possible contribution of COX-2 to the mechanism by which
AA and CYP2E1 increase COL1A2 mRNA levels in stellate cells. COX-2
and prostaglandin E2 synthesis were markedly increased in
E5 cells compared with control cells. NS-398, a COX-2 inhibitor, did
not modulate either basal or ethanol-induced levels of COL1A2 mRNA
in D21 or E5 cells. By contrast, AA-mediated induction of COL1A2
expression was suppressed by NS-398. These results suggest that
metabolites produced by the oxidation of AA by COX-2 are responsible
for the increase in COL1A2 expression when AA is added to the E5 cells.
A model can be proposed that links CYP2E1-dependent
production of reactive oxygen species, sensitivity to antioxidants such as catalase, COX-2 induction, and COL1A2
expression (Fig. 9); CYP2E1-dependent production of reactive oxygen species such
as H2O2, among others, activates COL1A2
expression, and this stimulation is catalase-sensitive and
augmented by ethanol. COX-2 expression is also increased by
CYP2E1-derived reactive oxygen species; however, in the absence of AA,
there were only very modest increases in COX-2-derived metabolites such
as prostaglandin E2. Hence, the expression of COL1A2
in the E5 cells or its augmentation by ethanol is not sensitive to
NS-398, although COX-2 itself is increased in the E5 cells (Fig.
6A). When AA is added, there is a marked increase in the
production of COX-2-derived metabolites (Fig. 6B) in
association with enhanced COL1A2 expression. The finding that NS-398 inhibits both prostaglandin E2 production and
the AA stimulation of COL1A2 expression directly links both
events to a COX-2-dependent mechanism. The ability of
catalase and ebselen to decrease COL1A2 expression may
reflect the removal of H2O2 (or
H2O2-derived oxidants) with the subsequent
down-regulation of COL1A2 and possibly COX-2
expression. It is important to note that ebselen inhibits
lipoxygenase and cyclooxygenase activity, in addition to removal of
H2O2 and lipid hydroperoxides (59); PBN,
besides scavenging a variety of free radicals, acts also as an
anti-inflammatory agent because it decreases steady-state COX-2
mRNA levels and COX-2 catalytic activity in macrophages (60).
Therefore, the prevention of the AA-induced increase in COL1A2
expression by ebselen and PBN may occur by several mechanisms.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 9.
Proposed mechanism for the ethanol- and
AA-mediated induction of COL1A2 gene expression in E5
cells. Described under "Discussion."
|
|
In liver disease, antioxidant levels are depleted in whole liver.
Depletion of antioxidants in stellate cells also occurs and could be
related to their fibrogenic capacity (42). Reducing oxidative stress is
a relatively practical avenue of intervention to prevent liver fibrosis
(42). Antioxidants, such as vitamin E, suppress fibrogenesis in some
but not all studies of experimental fibrogenesis (61). Recent studies
have documented inhibition of stellate cell activation by resveratrol,
quercetin, and N-acetylcysteine (62). Silymarin reduces
collagen accumulation by 30% in secondary biliary fibrosis in rats via
its antioxidant activity (63). The antifibrotic properties of these
flavonoids rely on their antioxidant effects (63). The powerful
inhibition of COL1A2 expression by catalase and ebselen in
the CYP2E1 stellate cell model suggests that agents that efficiently
remove H2O2 may be especially promising in
preventing stellate cell activation and alcoholic liver disease.
 |
FOOTNOTES |
*
These studies were supported by United States Public Health
Services Grants AA03312 and AA06610 from the National Institute on
Alcohol Abuse and Alcoholism (NIAAA) (to A. I. C.), DK37340 from
NIDDK, National Institutes of Health (to S. L. F.), and AA12196 from
NIAAA and a grant from the American Liver Foundation (to P. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Biology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. Tel.: 212-241-7285; Fax: 212-996-7214;
E-mail: Arthur.Cederbaum@mssm.edu.
Published, JBC Papers in Press, April 17, 2000, DOI 10.1074/jbc.M001422200
 |
ABBREVIATIONS |
The abbreviations used are:
HSC(s), hepatic stellate cell(s);
AA, arachidonic acid;
CAT, chloramphenicol
acetyltransferase;
COL1A2, alpha 2 collagen type I;
COX, cyclooxygenase;
CYP2E1, cytochrome P450 2E1;
DAS, diallylsulfide;
DCF-DA, 2',7'-dichlorofluorescein diacetate;
MTT, 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium;
PBN, N-t-butyl-
-phenyl-nitrone;
TGF, transforming
growth factor.
 |
REFERENCES |
| 1.
|
Kawada, N.
(1997)
Histol. Histopathol.
12,
1069-1080
|
| 2.
|
Lang, A.,
and Brenner, D. A.
(1999)
Ital. J. Gastroenterol. Hepatol.
31,
173-179
|
| 3.
|
Casini, A.,
Ceni, E.,
Salzano, R.,
Biondi, P.,
Parola, M.,
Galli, A.,
Foschi, M.,
Caligiuri, A.,
Pinzani, M.,
and Surrenti, C.
(1997)
Hepatology
25,
361-367
|
| 4.
|
Gorsky, L. D.,
Koop, D. R.,
and Coon, M. J.
(1984)
J. Biol. Chem.
259,
6812-6817
|
| 5.
|
Ekstrom, G.,
and Ingelman-Sundberg, M.
(1989)
Biochem. Pharmacol.
38,
1313-1319
|
| 6.
|
Rashba-Step, J.,
Turro, N. J.,
and Cederbaum, A. I.
(1993)
Arch. Biochem. Biophys.
300,
401-408
|
| 7.
|
Nieto, N.,
Friedman, S. L.,
Greenwel, P.,
and Cederbaum, A. I.
(1999)
Hepatology
30,
987-996
|
| 8.
|
Lieber, C. S.
(1994)
Physiol. Rev.
77,
517-544
|
| 9.
|
Albano, E.,
French, S. W.,
and Ingelman-Sundberg, M.
(1999)
Front. Biosci.
4,
D533-D540
|
| 10.
|
Song, B. J.,
Gelboin, H. V.,
Park, S. S.,
Yang, C. S.,
and Gonzalez, F. J.
(1986)
J. Biol. Chem.
261,
16689-16697
|
| 11.
|
Koop, D. R.,
and Tierney, D. J.
(1990)
Bioessays
12,
429-435
|
| 12.
|
Tsukamoto, H.,
Matsuoka, M.,
and French, S.
(1990)
Semin. Liver Dis.
10,
56-63
|
| 13.
|
Nanji, A. A.,
and French, S. W.
(1989)
Life Sci.
44,
223-227
|
| 14.
|
Nanji, A. A.,
Griniuviene, B.,
Sadrzadeh, S. M. H.,
Levitsky, S.,
and McCully, J. D.
(1995)
J. Lipid. Res.
36,
736-744
|
| 15.
|
Bedossa, P.,
Houglum, K.,
Trautwein, C.,
Holstege, A.,
and Chojkier, M.
(1994)
Hepatology
19,
1262-1271
|
| 16.
|
Chen, Q.,
Galleano, M.,
and Cederbaum, A. I.
(1997)
J. Biol. Chem.
272,
14532-14541
|
| 17.
|
Kim, Y.,
Ratziu, V.,
Choi, S.-G.,
Lalazar, A.,
Theiss, G.,
Kim, S.-J.,
and Friedman, S. L.
(1998)
J. Biol. Chem.
273,
33750-33758
|
| 18.
|
Lowry, O. H.,
Rosebrough, N. J.,
Farr, A. L.,
and Randall, R. J.
(1951)
J. Biol. Chem.
193,
265-275
|
| 19.
|
Boast, S.,
Su, M. W.,
Ramirez, F.,
Sanchez, M.,
and Avvedimento, E. V.
(1990)
J. Biol. Chem.
265,
13351-13356
|
| 20.
|
Maniatis, T.,
Fritsch, E. F.,
and Sambrook, J.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 21.
|
Carter, W. O.,
Narajanan, P. K.,
and Robinson, J. P.
(1994)
J. Leukocyte Biol.
55,
253-258
|
| 22.
|
Kuypers, F. A.,
Van den Berg, J. J. M.,
Schalkwijk, C.,
Roelofsen, B.,
and Op den Kamp, J. A. F.
(1987)
Biochim. Biophys. Acta
921,
266-274
|
| 23.
|
Myers, J. C.,
Dickson, L. A.,
de Wet, W. J.,
Bernard, M. P.,
Chu, M. L.,
Di Liberto, M.,
Pepe, G.,
Sangiorgi, F. O.,
and Ramirez, F.
(1983)
J. Biol. Chem.
258,
10128-10135
|
| 24.
|
Zhang, F.,
Subbaramaiah, K.,
Altorki, N.,
and Dannenberg, A. J.
(1998)
J. Biol. Chem.
273,
2424-2428
|
| 25.
|
Nordmann, R.,
Ribiere, C.,
and Rouach, H.
(1992)
Free Radic. Biol. Med.
12,
219-240
|
| 26.
|
Castillo, T.,
Koop, D. R.,
Kamimura, S.,
Triadafilopoulos, G.,
and Tsukamoto, H.
(1992)
Hepatology
16,
992-996
|
| 27.
|
Niemela, O.,
Parkkila, S.,
Pasanen, M.,
Ismuro, Y.,
Bradford, B.,
and Thurman, R. G.
(1998)
Alcohol. Clin. Exp. Res.
22,
2118-2124
|
| 28.
|
Albano, E.,
Clot, P.,
Morimoto, M.,
Tomasi, A.,
Ingelman-Sundberg, M.,
and French, S. W.
(1996)
Hepatology
23,
155-163
|
| 29.
|
Morimoto, M.,
Hagbjork, A. L.,
Wan, Y. J.,
Fu, P. C.,
Clot, P.,
Albano, E.,
Ingelman-Sundberg, M.,
and French, S. W.
(1995)
Hepatology
21,
1610-1617
|
| 30.
|
French, S. W.,
Morimoto, M.,
Reitz, R. C.,
Koop, D.,
Klopfenstein, B.,
Estes, K.,
Clot, P.,
Ingelman-Sundberg, M.,
and Albano, E.
(1997)
J. Nutr.
127,
907-911 (suppl.)
|
| 31.
|
Nanji, A. A.,
Zhao, S.,
Sadrzadeh, S. M. H.,
Dannenberg, A. J.,
Tahan, S. R.,
and Waxman, D.
(1994)
Alcohol. Clin. Exp. Res.
18,
1280-1285
|
| 32.
|
Pratico, D.,
Iuliano, L.,
Basili, S.,
Ferro, D.,
Camastra, C.,
Cordova, C.,
Fitzgerald, G. A.,
and Violi, F.
(1998)
J. Investig. Med.
46,
51-57
|
| 33.
|
Thomas, C. E.,
Ohlweiler, D. F.,
Carr, A. A.,
Nieduzak, T. R.,
Hay, D. A.,
Adams, G.,
Vaz, R.,
and Bernotas, R. C.
(1996)
J. Biol. Chem.
271,
3097-3104
|
| 34.
|
Müller, A.,
Cadenas, E.,
Graf, P.,
and Sies, H.
(1984)
Biochem. Pharmacol.
33,
3235-3239
|
| 35.
|
Maiorino, M.,
Roveri, A.,
Coassin, M.,
and Ursini, F.
(1988)
Biochem. Pharmacol.
37,
2267-2271
|
| 36.
|
Brady, J. F.,
Ishizaki, H.,
Fukuto, J. M.,
Lin, M. C.,
Fadel, A.,
Gaspae, J. M.,
and Yang, C. S.
(1991)
Chem. Res. Toxicol.
4,
642-647
|
| 37.
|
Nanji, A. A.,
Zakim, D.,
Rahemtulla, A.,
Thomas, A.,
Miao, L.,
Zhao, S.,
Khwaja, S.,
Tahan, S. R.,
and Dannenberg, A. J.
(1997)
Hepatology
26,
1538-1545
|
| 38.
|
Adderley, S. R.,
and Fitzgerald, D. J.
(1999)
J. Biol. Chem.
274,
5038-5046
|
| 39.
|
Tsugawa, K.,
Hashizume, M.,
Migou, S.,
Kishihara, F.,
Kawanaka, H.,
Tomikawa, M.,
and Sugimachi, K.
(1999)
J. Gastroenterol. Hepatol.
14,
642-651
|
| 40.
|
Inagaki, Y.,
Truter, S.,
Greenwel, P.,
Rojkind, M.,
Unoura, M.,
Kobayashi, K.,
and Ramirez, F.
(1995)
Hepatology
22,
573-579
|
| 41.
|
Li, D.,
and Friedman, S. L.
(1999)
J. Gastroenterol. Hepatol.
14,
618-633
|
| 42.
|
Friedman, S. L.
(2000)
J. Biol. Chem.
275,
2247-2250
|
| 43.
|
Yamada, T.,
Imaoka, S.,
Kawada, N.,
Seki, S.,
Kuroki, T.,
Tobayasi, K.,
and Monna, T.
(1997)
Life Sci
61,
171-179
|
| 44.
|
Oinonen, T.,
Koivisto, T.,
and Lindros, K. O.
(1998)
Biochem. Pharmacol.
56,
1075-1078
|
| 45.
|
Casini, A.,
Pellegrini, G.,
Ceni, E.,
Salzano, R.,
Parola, M.,
Robino, G.,
and Mirani, S.
(1998)
J. Hepatol.
28,
40-45
|
| 46.
|
Pares, A.,
Potter, J. J.,
Rennie, L.,
and Mezey, E.
(1994)
Hepatology
19,
498-503
|
| 47.
|
Greenwel, P.,
Inagaki, Y.,
Hu, W.,
Walsh, M.,
and Ramirez, F.
(1997)
J. Biol. Chem.
272,
19738-19745
|
| 48.
|
Inagaki, Y.,
Truter, S.,
Tanaka, S.,
Di Liberto, M.,
and Ramirez, F.
(1995)
J. Biol. Chem.
270,
3353-3358
|
| 49.
|
Inagaki, Y.,
Truter, S.,
and Ramirez, F.
(1994)
J. Biol. Chem.
269,
14828-14834
|
| 50.
|
Rossi, P.,
Karsenty, G.,
Roberts, A. B.,
Roche, N. S.,
Sporn, M. B.,
and de Crombrugghe, B.
(1988)
Cell
52,
405-414
|
| 51.
|
Chung, K.-Y.,
Agarwal, A.,
Uitto, J.,
and Mauviel, A.
(1996)
J. Biol. Chem.
271,
3272-3278
|
| 52.
|
Greenwel, P.,
Dominguez-Rosales, J. A.,
Mavi, G.,
Rivas-Estilla, A. M.,
and Rojkind, M.
(2000)
Hepatology
31,
109-116
|
| 53.
|
Garcia-Trevijano, E. R.,
Iraburu, M. J.,
Fontana, L.,
Dominguez-Rosales, J. A.,
Auster, A.,
Covarrubias-Pinedo, A.,
and Rojkind, M.
(1999)
Hepatology
29,
960-970
|
| 54.
|
Lieber, C. S.
(1999)
Alcohol. Clin. Exp. Res.
6,
991-1007
|
| 55.
|
Brenner, D. A.,
and Chojkier, M.
(1987)
J. Biol. Chem.
262,
17690-17695
|
| 56.
|
Thurman, R. G.
(1973)
Mol. Pharmacol.
9,
670-675
|
| 57.
|
Matsuura, H.,
Sakaue, M.,
Subbaramaiah, K.,
Kamitani, H.,
Eling, T. E.,
Dannenberg, A. J.,
Tanabe, T.,
Inoue, H.,
Arata, J.,
and Jetten, A. M.
(1999)
J. Biol. Chem.
274,
29138-29148
|
| 58.
|
Feng, L.,
Xia, Y.,
Garcia, G. E.,
Hwang, D.,
and Wilson, C. B.
(1995)
J. Clin. Invest.
95,
1669-1675
|
| 59.
|
Hurst, J. S.,
Paterson, C. A.,
Bhattacherjee, P.,
and Pierce, W. M.
(1989)
Biochem. Pharmacol.
38,
3357-3363
|
| 60.
|
Kotake, Y.,
Sang, H.,
Miyajima, T.,
and Wallis, G. L.
(1998)
Biochim. Biophys. Acta
1448,
77-84
|
| 61.
|
Pietrangelo, A.,
Gualdi, R.,
Casalgrandi, G.,
Montosi, G.,
and Ventura, E.
(1995)
J. Clin. Invest.
95,
1824-1831
|
| 62.
|
Kawada, N.,
Seki, S.,
Inoue, M.,
and Kuroki, T.
(1998)
Hepatology
27,
1265-1274
|
| 63.
|
Boigk, G.,
Stroedter, L.,
Herbst, H.,
Waldchmidt, J.,
Riecken, E. O.,
and Schuppan, D.
(1997)
Hepatology
26,
643-649
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit